MTOR and hepatocellular carcinoma: Collectively, the results of these studies reveal that DDX11 exerts a pro-tumorigenic activity via PI3K/AKT/mTOR [54] and E2F/EZH2/p21 [55] signaling pathways in HCC (see Figure 4) and suggest that DDX11 can be a novel prognostic biomarker for this cancer type.